HIV Infections Clinical Trial
This study will examine how HIV affects the brain and nervous system, learning, and behavior
in children on highly active antiretroviral therapy (HAART). Although HAART has resulted in
fewer HIV-infected children getting sick and even fewer dying from AIDS, many children on
this treatment regimen develop significant brain or nervous system problems, such as learning
difficulties, attention problems, hyperactivity, and depression.
People who acquired HIV disease in the first decade of life and who have evidence of central
nervous system (CNS) disease (e.g., encephalopathy, CNS compromise, ADHD, bipolar disease,
major depression or psychosis) may be eligible for this study. Candidates are screened with a
medical history, physical examination, neuropsychological testing and a CT scan of the head,
if one has not been done within 12 months of entering the study.
Participants undergo the following tests and procedures:
- MRI and MRS scan of the head: These tests use a magnetic field and radio waves to obtain
images of the brain and detect changes in certain brain chemicals that may be affected
by HIV infection. Both procedures are done at the same time. The patient lies on a table
that is moved into the scanner (a narrow cylinder), wearing earplugs to muffle loud
knocking and thumping sounds that occur during the scanning process. The procedure lasts
about 50 to 60 minutes, during which time the patient can communicate with the staff.
- Neuropsychological testing: Patients' thinking and behavior are evaluated with tests to
measure their memory, attention, language, problem-solving, academic, and motor skills
and questionnaires to assess behavioral and emotional functioning, quality of life, and
adherence to HIV medication. Parents are also asked to complete questionnaires assessing
their child's behavioral and emotional functioning, quality of life, important life
events, and adherence to HIV medication.
- Lumbar puncture (spinal tap): Cerebrospinal fluid (CSF) is collected for analysis. For
this procedure, a local anesthetic is given and a needle is inserted in the space
between the bones in the lower back where the CSF circulates below the spinal cord. Some
fluid is collected through the needle. Blood tests and a physical examination are done
before the procedure to make sure it can be done as safely as possible. Patients may
also be sedated to prevent any discomfort.
- Follow-up: The blood tests, MRI and MRS scans and spinal tap are repeated 1 and 2 years
after the initial evaluation.
Some blood and spinal fluid samples from participants are stored for possible future studies
related to HIV research
Background:
Highly active antiretroviral therapy (HAART) has altered the natural history of HIV disease
in children.
A significant minority of HIV-infected children has evidence of ongoing CNS disease.
Specific markers for CNS disease, factors predictive of risk for neurological decline, and
pathophysiologic mechanisms have not yet been identified in HIV-infected children.
Objective:
To explore the clinical features (neurological and psychiatric exams, neuropsychological
evaluation, and neuroimaging), viral and neuroinflammatory factors, anatomic changes (brain
MRI) and patterns of brain metabolites (1H-MRS) associated with HIV-related CNS disease in
HIV-infected children in the HAART era.
Eligibility:
HIV disease acquired in the first decade of life.
Evidence of CNS disease (classification of encephalopathy or CNS compromise or diagnosis of
ADHD, bipolar disease, major depression, or psychosis).
Design:
Serial neurologic and psychiatric examinations, neuropsychologic test, neuroimaging, and CSF
sampling will be performed once a year for a total of 3 evaluations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |